Neon Therapeutics, Inc. (NTGN)
May 6, 2020 - NTGN was delisted
(reason: acquired by BNTX)Stock Price:
$3.07 USD
0.00 (0.00%)
Updated May 6, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
88.92M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-75.35M |
| Shares Out |
28.97M |
| EPS (ttm) |
-2.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
May 6, 2020 |
| Last Price |
$3.07 |
| Previous Close |
$3.07 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
2.92 - 3.09 |
| Day's Volume |
0 |
| 52-Week Range |
0.88 - 6.15 |
More Stats
| Market Cap |
88.92M |
| Enterprise Value |
81.36M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
28.97M |
| Float |
15.08M |
| EPS (basic) |
-2.68 |
| EPS (diluted) |
-2.68 |
| FCF / Share |
-2.33 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
743,908 |
| Short Ratio |
1.29 |
| Short % of Float |
4.84% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
6.16 |
| Revenue |
n/a |
| Operating Income |
-76.22M |
| Net Income |
-75.35M |
| Free Cash Flow |
-66.60M |
| Net Cash |
7.56M |
| Net Cash / Share |
0.26 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-70.63% |
| ROE |
-156.16% |
| ROIC |
-402.40% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (3)
| Buy |
1 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Analyst Consensus: Overweight
Low
2.00
Current: 3.07
High
2.00
Target: 2.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -81.14 | -78.70 | -48.09 | -27.42 |
| Net Income | -79.78 | -76.93 | -47.54 | -27.43 |
| Shares Outstanding | 27.88 | 15.04 | 1.69 | 0.99 |
| Earnings Per Share | -2.86 | -5.54 | -34.32 | -30.72 |
| Operating Cash Flow | -73.41 | -63.43 | -41.28 | -24.16 |
| Capital Expenditures | -1.08 | -3.22 | -3.24 | -2.36 |
| Free Cash Flow | -74.50 | -66.65 | -44.52 | -26.51 |
| Cash & Equivalents | 29.40 | 103 | 79.73 | 88.49 |
| Total Debt | 7.78 | - | - | - |
| Net Cash / Debt | 21.61 | 103 | 79.73 | 88.49 |
| Assets | 46.37 | 114 | 90.49 | 95.26 |
| Liabilities | 16.96 | 12.84 | 8.82 | 5.04 |
| Book Value | 29.42 | 101 | -93.57 | -38.49 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Neon Therapeutics, Inc. |
| Country |
United States |
| Employees |
71 |
Stock Information
| Ticker Symbol |
NTGN |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: NTGN |
| IPO Date |
June 27, 2018 |
Description
Neon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial for the treatment of advanced or metastatic non-small cell lung cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of hormone-receptor-positive breast cancer, as well as NEO-STC-01, a neoantigen adoptive T cell therapy for the treatment of cancers driven or mediated by RAS mutations. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.